Fig. 2: Survival analysis regarding IKZF1 mutation status in acute myeloid leukemia.
From: Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
Survival analysis using Kaplan–Meier estimators and the log-rank test. First, differences in survival times were analyzed comparing mutated (mut.) vs. wildtype (wt) IKZF1 (A–C). AML patients with mut. IKZF1 (red) show significantly decreased event-free (A), relapse-free (B), and overall survival (C) compared to AML patients with wt IKZF1 (blue). The hotspot mutation N159S confers decreased event-free (D), relapse-free (E), and overall survival (F) while patients harboring non-N159S IKZF1 (other) alterations find themselves in between IKZF1-N159S and wt patients with regard to survival times. Survival times in months. Boldface indicates statistical significance (p < 0.05).
